Summary:
Enada NADH, otherwise known as nicotinimide adenine dinucleotide, has proven itself to be remarkably useful in treating degenerative medical disorders. Those looking for a treatment for Parkinson's disease have found that depending on the stage of the disease before treatment, NADH yields many improvements.

Close to 3,000 European patients with Parkinson's disease have witnessed astounding improvements after nutritionally supplementing their diet with NADH. In other words, about 80 % of patients seen in Europe that suffer from Parkinson's disease experienced great improvements when treated with NADH. In the remaining percentage of patients who witnessed no change in condition, the disease had progressed to far, resulting in to much damage to the brain.

What characterizes Parkinson's disease?
Parkinson's disease is a degenerative brain disorder associated with several symptoms such as trembling and muscular rigidty, depression, and mental impairment. Usually appearing near the age of 40, the disease may eventually lead to incapacity as the brain cells which produce dopamine become inert.

A recent clinical trial investigating how the body can best and most efficiently use NADH, studied the responses of 885 patients with Parkinson's disease to NADH. Some patients received the compound by intravenous infusion while others received oral tablets. Reasearchers found that the oral supplement yielded greater results.